Valproate

Last updated

Valproate
INN: valproic acid
2-propylpentanoic acid 200.svg
Valproic acid-optimized-ball-and-stick-model.png
Clinical data
Trade names Depakote, Epilim, Convulex, others
Other namesVPA; valproic acid; sodium valproate (sodium); valproate semisodium (semisodium); 2-propylvaleric acid
AHFS/Drugs.com Monograph
MedlinePlus a682412
License data
Pregnancy
category
  • AU:D
Routes of
administration 		By mouth, intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability Rapid absorption
Protein binding 80–90% [6]
Metabolism Liver—glucuronide conjugation 30–50%, mitochondrial β-oxidation over 40%
Elimination half-life 9–16 hours [6]
Excretion Urine (30–50%) [6]
Identifiers
  • 2-propylpentanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
ECHA InfoCard 100.002.525 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C8H16O2
Molar mass 144.214 g·mol−1
3D model (JSmol)
  • O=C(O)C(CCC)CCC
  • InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10) Yes check.svgY
  • Key:NIJJYAXOARWZEE-UHFFFAOYSA-N Yes check.svgY
   (verify)

Valproate (valproic acid, VPA, sodium valproate, and valproate semisodium forms) are medications primarily used to treat epilepsy and bipolar disorder and prevent migraine headaches. [7] They are useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures. [7] They can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations. [7]

Contents

Common side effects of valproate include nausea, vomiting, somnolence, and dry mouth. [7] Serious side effects can include liver failure, and regular monitoring of liver function tests is therefore recommended. [7] Other serious risks include pancreatitis and an increased suicide risk. [7] Valproate is known to cause serious abnormalities or birth defects in the unborn child if taken during pregnancy, [7] [8] and is contra-indicated for women of childbearing age unless the drug is essential to their medical condition and the person is also prescribed a contraceptive. [7] [9] [4] Reproductive warnings have also been issued for men using the drug. [10] The United States Food and Drug Administration has indicated a black box warning given the frequency and severity of the side effects and teratogenicity. [4] Additionally, there is also a black box warning due to risk of hepatotoxicity and pancreatitis. [11] As of 2022 the drug was still prescribed in the UK to potentially pregnant women, but use declined by 51% from 2018–19 to 2020–21. [12]

Valproate's precise mechanism of action is unclear. [7] [13] Proposed mechanisms include affecting GABA levels, blocking voltage-gated sodium channels, inhibiting histone deacetylases, and increasing LEF1. [14] [15] [16] Valproic acid is a branched short-chain fatty acid (SCFA), a derivative of valeric acid. [14]

Valproate was originally synthesized in 1881 and came into medical use in 1962. [17] It is on the World Health Organization's List of Essential Medicines. [18] It is available as a generic medication. [7] In 2022, it was the 174th most commonly prescribed medication in the United States, with more than 2 million prescriptions. [19] [20]

Medical uses

500mg tablets of Depakote extended-release Depakote 500mg ER.jpg
500mg tablets of Depakote extended-release

Valproate or valproic acid is used primarily to treat epilepsy and bipolar disorder and to prevent migraine headaches. [21]

Epilepsy

Valproate has a broad spectrum of anticonvulsant activity, although it is primarily used as a first-line treatment for tonic–clonic seizures, absence seizures and myoclonic seizures and as a second-line treatment for partial seizures and infantile spasms. [21] [22] It has also been successfully given intravenously to treat status epilepticus. [23] [24]

In the US, valproic acid is also prescribed as an anti-epileptic drug indicated for the treatment of manic episodes associated with bipolar disorder; monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in people with multiple seizure types that include absence seizures. [4] [5]

Mental illness

Valproate products are used to treat manic or mixed episodes of bipolar disorder. [25] [26]

A 2016 systematic review compared the efficacy of valproate as an add-on for people with schizophrenia: [27]

There is limited evidence that adding valproate to antipsychotics may be effective for overall response and also for specific symptoms, especially in terms of excitement and aggression. Valproate was associated with a number of adverse events among which sedation and dizziness appeared more frequently than in the control groups. [27]

Other neurological indications

Based upon five case reports, valproic acid may have efficacy in controlling the symptoms of the dopamine dysregulation syndrome that arise from the treatment of Parkinson's disease with levodopa. [28] [29] [30]

Valproate is not commonly used to prevent or treat migraine headaches, but it may be prescribed if other medications are effective. [31]

Other

The medication has been tested in the treatment of AIDS and cancer, owing to its histone-deacetylase-inhibiting effects.[ citation needed ] It has cardioprotective, kidney protective, antiinflammatory, and antimicrobial effects. [32]

Contraindications

Contraindications include:

Adverse effects

Most common adverse effects include: [4]

Serious adverse effects include: [4]

Valproic acid has a black box warning for hepatotoxicity, pancreatitis, and fetal abnormalities. [4]

There is evidence that valproic acid may cause premature growth plate ossification in children and adolescents, resulting in decreased height. [36] [37] [38] Valproic acid can also cause mydriasis, a dilation of the pupils. [39] There is evidence that shows valproic acid may increase the chance of polycystic ovary syndrome (PCOS) in women with epilepsy or bipolar disorder. Studies have shown this risk of PCOS is higher in women with epilepsy compared to those with bipolar disorder. [40] Weight gain is also possible. [41]

Pregnancy

This section is an excerpt from Fetal valproate spectrum disorder.[ edit ]
Minor limb malformations seen after valproate exposure Minor Limb Malformations Seen After Valproate Exposure.webp
Minor limb malformations seen after valproate exposure
Fetal valproate spectrum disorder (FVSD), previously known as fetal valproate syndrome (FVS), is a rare disease caused by prenatal exposure to valproic acid (VPA), a medication commonly used to treat epilepsy, bipolar disorder, and migraines. This exposure can lead to a range of neurodevelopmental and physical symptoms, including cognitive impairments, developmental delays, autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), and congenital malformations. [42] [43] [44]

Elderly

Valproate may cause increased somnolence in the elderly. In a trial of valproate in elderly patients with dementia, a significantly higher portion of valproate patients had somnolence compared to placebo. In approximately one-half of such patients, there was associated reduced nutritional intake and weight loss. [4]

Overdose and toxicity

Therapeutic range of valproic acid
FormLower limitUpper limitUnit
Total (including
protein bound)		50 [45] 125 [45] μg/mL or mg/L
350 [46] 700 [46] μmol/L
Free6 [45] 22 [45] μg/mL or mg/L
35 [46] 70 [46] μmol/L

Excessive amounts of valproic acid can result in somnolence, tremor, stupor, respiratory depression, coma, metabolic acidosis, and death. In general, serum or plasma valproic acid concentrations are in a range of 20–100 mg/L during controlled therapy, but may reach 150–1500 mg/L following acute poisoning. Monitoring of the serum level is often accomplished using commercial immunoassay techniques, although some laboratories employ gas or liquid chromatography. [47] In contrast to other antiepileptic drugs, at present there is little favorable evidence for salivary therapeutic drug monitoring. Salivary levels of valproic acid correlate poorly with serum levels, partly due to valproate's weak acid property (pKa of 4.9). [48]

In severe intoxication, hemoperfusion or hemofiltration can be an effective means of hastening elimination of the drug from the body. [49] [50] Supportive therapy should be given to all patients experiencing an overdose and urine output should be monitored. [4] Supplemental L-carnitine is indicated in patients having an acute overdose [51] [52] and also prophylactically [51] in high risk patients. Acetyl-L-carnitine lowers hyperammonemia less markedly [53] than L-carnitine.

Interactions

Valproate inhibits CYP2C9, glucuronyl transferase, and epoxide hydrolase and is highly protein bound and hence may interact with drugs that are substrates for any of these enzymes or are highly protein bound themselves. [33] It may also potentiate the CNS depressant effects of alcohol. [33] It should not be given in conjunction with other antiepileptics due to the potential for reduced clearance of other antiepileptics (including carbamazepine, lamotrigine, phenytoin and phenobarbitone) and itself. [33] It may also interact with: [4] [33] [54]

Pharmacology

Pharmacodynamics

Although the mechanism of action of valproate is not fully understood, [33] traditionally, its anticonvulsant effect has been attributed to the blockade of voltage-gated sodium channels and increased brain levels of the inhibitory synaptic neurotransmitter gamma-aminobutyric acid (GABA). [33] The GABAergic effect is also believed to contribute towards the anti-manic properties of valproate. [33] In animals, sodium valproate raises cerebral and cerebellar levels of GABA, possibly by inhibiting GABA degradative enzymes, such as GABA transaminase, succinate-semialdehyde dehydrogenase and by inhibiting the re-uptake of GABA by neuronal cells. [33] Prevention of neurotransmitter-induced hyperexcitability of nerve cells via Kv7.2 channel and AKAP5 may also contribute to its mechanism. [55] Valproate has been shown to protect against a seizure-induced reduction in phosphatidylinositol (3,4,5)-trisphosphate (PIP3) as a potential therapeutic mechanism. [56]

Valproate is a histone deacetylase inhibitor. By inhibition of histone deacetylase, it promotes more transcriptionally active chromatin structures, that is it exerts an epigenetic effect. This has been proven in mice: Valproic acid induced histone hyperacetylation had brain function effects on the next generation of mice through changes in sperm DNA methylation. [57] Intermediate molecules include VEGF, BDNF, and GDNF. [58] [59]

Endocrine actions

Valproic acid has been found to be an antagonist of the androgen and progesterone receptors, and hence as a nonsteroidal antiandrogen and antiprogestogen, at concentrations much lower than therapeutic serum levels. [60] In addition, the drug has been identified as a potent aromatase inhibitor, and suppresses estrogen concentrations. [61] These actions are likely to be involved in the reproductive endocrine disturbances seen with valproic acid treatment. [60] [61]

Valproic acid has been found to directly stimulate androgen biosynthesis in the gonads via inhibition of histone deacetylases and has been associated with hyperandrogenism in women and increased 4-androstenedione levels in men. [62] [63] High rates of polycystic ovary syndrome and menstrual disorders have also been observed in women treated with valproic acid. [63]

Pharmacokinetics

Some metabolites of valproic acid. Glucuronidation and b-oxidation are the main metabolic pathways; o-oxidation metabolites are considered hepatotoxic. Details see text. Valproic acid metabolism.svg
Some metabolites of valproic acid. Glucuronidation and β-oxidation are the main metabolic pathways; ω-oxidation metabolites are considered hepatotoxic. Details see text.

Taken by mouth, valproate is rapidly and virtually completely absorbed from the gut. [64] When in the bloodstream, 80–90% of the substance are bound to plasma proteins, mainly albumin. Protein binding is saturable: it decreases with increasing valproate concentration, low albumin concentrations, the patient's age, additional use of other drugs such as aspirin, as well as liver and kidney impairment. [66] [67] Concentrations in the cerebrospinal fluid and in breast milk are 1 to 10% of blood plasma concentrations. [64]

The vast majority of valproate metabolism occurs in the liver. [68] Valproate is known to be metabolized by the cytochrome P450 enzymes CYP2A6, CYP2B6, CYP2C9, and CYP3A5. [68] It is also known to be metabolized by the UDP-glucuronosyltransferase enzymes UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15. [68] Some of the known metabolites of valproate by these enzymes and uncharacterized enzymes include (see image): [68]

All in all, over 20 metabolites are known. [64]

In adult patients taking valproate alone, 30–50% of an administered dose is excreted in urine as the glucuronide conjugate. [68] The other major pathway in the metabolism of valproate is mitochondrial beta oxidation, which typically accounts for over 40% of an administered dose. [68] Typically, less than 20% of an administered dose is eliminated by other oxidative mechanisms. [68] Less than 3% of an administered dose of valproate is excreted unchanged (i.e., as valproate) in urine. [68] Only a small amount is excreted via the faeces. [64] Elimination half-life is 16±3 hours and can decrease to 4–9 hours when combined with enzyme inducers. [64] [67]

Chemistry

Valproic acid is a branched short-chain fatty acid and the 2-n-propyl derivative of valeric acid. [14]

History

Valproic acid was first synthesized in 1882 by Beverly S. Burton as an analogue of valeric acid, found naturally in valerian. [69] Valproic acid is a carboxylic acid, a clear liquid at room temperature. For many decades, its only use was in laboratories as a "metabolically inert" solvent for organic compounds. In 1962, the French researcher Pierre Eymard serendipitously discovered the anticonvulsant properties of valproic acid while using it as a vehicle for a number of other compounds that were being screened for antiseizure activity. He found it prevented pentylenetetrazol-induced convulsions in laboratory rats. [70] It was approved as an antiepileptic drug in 1967 in France and has become the most widely prescribed antiepileptic drug worldwide. [71] Valproic acid has also been used for migraine prophylaxis and bipolar disorder. [72]

Society and culture

Valproate is available as a generic medication. [7]

Approval status

Indications Flag of the United States.svg
FDA-labelled indication? [6] 		Flag of Australia (converted).svg
TGA-labelled indication? [21] 		Flag of the United Kingdom.svg
MHRA-labelled indication? [73] 		Literature support
EpilepsyYesYesYesLimited (depends on the seizure type; it can help with certain kinds of seizures: drug-resistant epilepsy, partial and absence seizures, can be used against glioblastoma and other tumors both to improve survival and treat seizures, and against tonic–clonic seizures and status epilepticus). [74] [75] [76] [77]
Bipolar maniaYesYesYesLimited. [78] [ failed verification ]
Bipolar depressionNoNoNoModerate. [79]
Bipolar maintenanceNoNoNoLimited. [80]
Migraine prophylaxisYesYes (accepted)NoLimited.
Acute migraine managementNoNoNoOnly negative results. [81]
SchizophreniaNoNoNoWeak evidence. [82]
Agitation in dementiaNoNoNoWeak evidence. Not recommended for agitation in people with dementia. [83] Increased rate of adverse effects, including a risk of serious adverse effects. [83]
Fragile X syndrome Yes (orphan)NoNoLimited. [59]
Familial adenomatous polyposis Yes (orphan)NoNoLimited.
Chronic pain & fibromyalgiaNoNoNoLimited. [84]
Alcohol hallucinosisNoNoNoOne randomised double-blind placebo-controlled trial. [85]
Intractable hiccupsNoNoNoLimited, five case reports support its efficacy, however. [86]
Non-epileptic myoclonusNoNoNoLimited, three case reports support its efficacy, however. [87]
Cluster headachesNoNoNoLimited, two case reports support its efficacy. [88]
West syndrome NoNoNoA prospective clinical trial supported its efficacy in treating infantile spasms. [89]
HIV infection eradicationNoNoNoDouble-blind placebo-controlled trials have been negative. [90] [91] [92]
Myelodysplastic syndrome NoNoNoSeveral clinical trials have confirmed its efficacy as a monotherapy, [93] as an adjunct to tretinoin [93] and as an adjunct to hydralazine. [94]
Acute myeloid leukaemia NoNoNoTwo clinical trials have confirmed its efficacy in this indication as both a monotherapy and as an adjunct to tretinoin. [95] [96] [97]
Cervical cancer NoNoNoOne clinical trial supports its use here. [98]
Malignant melanoma NoNoNoOne phase II study has seemed to discount its efficacy. [99]
Breast cancer NoNoNoA phase II study has supported its efficacy. [100]
Impulse control disorder NoNoNoLimited. [101] [102]

Off-label uses

In 2012, pharmaceutical company Abbott paid $1.6 billion in fines to US federal and state governments for illegal promotion of off-label uses for Depakote, including the sedation of elderly nursing home residents. [103] [104]

Some studies have suggested that valproate may reopen the critical period for learning absolute pitch and possibly other skills such as language. [105] [106]

Formulations

Sodium valproate
Sodium-valproate-2D-skeletal.png
Valproato Sodico.png
Clinical data
Other namesvalproate sodium (USAN US)
License data
Legal status
Legal status
Identifiers
  • sodium 2-propylpentanoate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.002.525 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C8H15NaO2
Molar mass 166.196 g·mol−1
3D model (JSmol)
  • CCCC(CCC)C(=O)[O-].[Na+]
  • InChI=1S/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-1 Yes check.svgY
  • Key:AEQFSUDEHCCHBT-UHFFFAOYSA-M Yes check.svgY
   (verify)
Valproate semisodium
Sodium valproate.svg 2-propylpentanoic acid 200.svg
Clinical data
Trade names Depakote, others
Other namessemisodium valproate, divalproex sodium (USAN US)
License data
Legal status
Legal status
Identifiers
  • sodium 2-propylpentanoate;2-propylpentanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.002.525 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C16H31NaO4
Molar mass 310.410 g·mol−1
3D model (JSmol)
  • CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]
  • InChI=1S/2C8H16O2.Na/c2*1-3-5-7(6-4-2)8(9)10;/h2*7H,3-6H2,1-2H3,(H,9,10);/q;;+1/p-1 Yes check.svgY
  • Key:MSRILKIQRXUYCT-UHFFFAOYSA-M Yes check.svgY

Valproate exists in two main molecular variants: sodium valproate and valproic acid without sodium (often implied by simply valproate). A mixture between these two is termed semisodium valproate. It is unclear whether there is any difference in efficacy between these variants, except from the fact that about 10% more mass of sodium valproate is needed than valproic acid without sodium to compensate for the sodium itself. [109]

Terminology

Valproate is a negative ion. The conjugate acid of valproate is valproic acid (VPA). Valproic acid is fully ionized into valproate at the physiologic pH of the human body, and valproate is the active form of the drug. Sodium valproate is the sodium salt of valproic acid. Divalproex sodium is a coordination complex composed of equal parts of valproic acid and sodium valproate. [110]

Brand names of valproic acid

Branded products include:

Brand names of sodium valproate

Portugal
  • Tablets – Diplexil-R by Bial.
United States
  • Intravenous injection – Depacon by Abbott Laboratories.
  • Syrup – Depakene by Abbott Laboratories. (Note: Depakene capsules are valproic acid).
  • Depakote tablets are a mixture of sodium valproate and valproic acid.
  • Tablets – Eliaxim by Bial.
Australia
  • Epilim Crushable Tablets Sanofi [113]
  • Epilim Sugar Free Liquid Sanofi [113]
  • Epilim Syrup Sanofi [113]
  • Epilim Tablets Sanofi [113]
  • Sodium Valproate Sandoz Tablets Sanofi
  • Valpro Tablets Alphapharm
  • Valproate Winthrop Tablets Sanofi
  • Valprease tablets Sigma
New Zealand
  • Epilim by Sanofi-Aventis

All the above formulations are Pharmac-subsidised. [114]

UK
  • Depakote Tablets (as in USA)
  • Tablets – Orlept by Wockhardt and Epilim by Sanofi
  • Oral solution – Orlept Sugar Free by Wockhardt and Epilim by Sanofi
  • Syrup – Epilim by Sanofi-Aventis
  • Intravenous injection – Epilim Intravenous by Sanofi
  • Extended release tablets – Epilim Chrono by Sanofi is a combination of sodium valproate and valproic acid in a 2.3:1 ratio.
  • Enteric-coated tablets – Epilim EC200 by Sanofi is a 200 mg sodium valproate enteric-coated tablet.
UK only
  • Capsules – Episenta prolonged release by Beacon
  • Sachets – Episenta prolonged release by Beacon
  • Intravenous solution for injection – Episenta solution for injection by Beacon
Germany, Switzerland, Norway, Finland, Sweden
  • Tablets – Orfiril by Desitin Pharmaceuticals
  • Intravenous injection – Orfiril IV by Desitin Pharmaceuticals
South Africa
  • Syrup – Convulex by Byk Madaus [115]
  • Tablets – Epilim by Sanofi-synthelabo
Malaysia
  • Tablets – Epilim (200 ENTERIC COATED) by Sanofi-Aventis
  • Controlled release tablets – Epilim Chrono (500 CONTROLLED RELEASE) by Sanofi-Aventis [116]
Romania
  • Companies are SANOFI-AVENTIS FRANCE, GEROT PHARMAZEUTIKA GMBH and DESITIN ARZNEIMITTEL GMBH
  • Types are Syrup, Extended release mini tablets, Gastric resistant coated tablets, Gastric resistant soft capsules, Extended release capsules, Extended release tablets and Extended release coated tablets
Canada
Japan
  • Tablets – Depakene by Kyowa Hakko Kirin
  • Extended release tablets – Depakene-R by Kyowa Hakko Kogyo and Selenica-R by Kowa
  • Syrup – Depakene by Kyowa Hakko Kogyo
Europe

In much of Europe, Dépakine and Depakine Chrono (tablets) are equivalent to Epilim and Epilim Chrono above.

Taiwan
Iran
  • Tablets – Epival 200 (enteric coated tablet) and Epival 500 (extended release tablet) by Iran Najo
  • Slow release tablets – Depakine Chrono by Sanofi Winthrop Industrie (France)
Israel

Depalept and Depalept Chrono (extended release tablets) are equivalent to Epilim and Epilim Chrono above. Manufactured and distributed by Sanofi-Aventis.

India, Russia and CIS countries
  • Valparin Chrono by Sanofi India
  • Valprol CR by Intas Pharmaceutical (India)
  • Encorate Chrono by Sun Pharmaceutical (India)
  • Serven Chrono by Leeven APL Biotech (India)
Uruguay
  • Tablets – DI DPA by Megalabs

Brand names of valproate semisodium

  • Brazil – Depakote by Abbott Laboratories and Torval CR by Torrent do Brasil
  • Canada – Epival by Abbott Laboratories
  • Mexico – Epival and Epival ER (extended release) by Abbott Laboratories
  • United Kingdom – Depakote (for psychiatric conditions) and Epilim (for epilepsy) by Sanofi-Aventis and generics
  • United States – Depakote and Depakote ER (extended release) by Abbott Laboratories and generics [4]
  • India – Valance and Valance OD by Abbott Healthcare Pvt Ltd, Divalid ER by Linux laboratories Pvt Ltd, Valex ER by Sigmund Promedica, Dicorate by Sun Pharma
  • Germany – Ergenyl Chrono by Sanofi-Aventis and generics
  • Chile – Valcote and Valcote ER by Abbott Laboratories
  • France and other European countries – Depakote
  • Peru – Divalprax by AC Farma Laboratories
  • China – Diprate OD

Research

A 2023 systematic review of the literature identified only one study in which valproate was evaluated in the treatment of seizures in infants aged 1 to 36 months. In a randomized control trial, valproate alone was found to show poorer outcomes for infants than valproate plus levetiracetam in terms of reduction of seizures, freedom from seizures, daily living ability, quality of life, and cognitive abilities. [117]

Related Research Articles

<span class="mw-page-title-main">Carbamazepine</span> Anticonvulsant medication

Carbamazepine, sold under the brand name Tegretol among others, is an anticonvulsant medication used in the treatment of epilepsy and neuropathic pain. It is used as an adjunctive treatment in schizophrenia along with other medications and as a second-line agent in bipolar disorder. Carbamazepine appears to work as well as phenytoin and valproate for focal and generalized seizures. It is not effective for absence or myoclonic seizures.

<span class="mw-page-title-main">Mood stabilizer</span> Psychiatric medication used to treat mood disorders

A mood stabilizer is a psychiatric medication used to treat mood disorders characterized by intense and sustained mood shifts, such as bipolar disorder and the bipolar type of schizoaffective disorder.

Anticonvulsants are a diverse group of pharmacological agents used in the treatment of epileptic seizures. Anticonvulsants are also increasingly being used in the treatment of bipolar disorder and borderline personality disorder, since many seem to act as mood stabilizers, and for the treatment of neuropathic pain. Anticonvulsants suppress the excessive rapid firing of neurons during seizures. Anticonvulsants also prevent the spread of the seizure within the brain.

<span class="mw-page-title-main">Ertapenem</span> Antibiotic medication

Ertapenem, sold under the brand name Invanz, is a carbapenem antibiotic medication used for the treatment of infections of the abdomen, the lungs, the upper part of the female reproductive system, and the diabetic foot.

<span class="mw-page-title-main">Lamotrigine</span> Medication used for bipolar disorder, epilepsy, & many seizure disorders

Lamotrigine, sold under the brand name Lamictal among others, is a medication used to treat epilepsy and stabilize mood in bipolar disorder. For epilepsy, this includes focal seizures, tonic-clonic seizures, and seizures in Lennox-Gastaut syndrome. In bipolar disorder, lamotrigine has not been shown to reliably treat acute depression in any groups except for the severely depressed; but for patients with bipolar disorder who are not currently symptomatic, it appears to reduce the risk of future episodes of depression.

Absence seizures are one of several kinds of generalized seizures. In the past, absence epilepsy was referred to as "pyknolepsy," a term derived from the Greek word "pyknos," signifying "extremely frequent" or "grouped". These seizures are sometimes referred to as petit mal seizures ; however, usage of this terminology is no longer recommended. Absence seizures are characterized by a brief loss and return of consciousness, generally not followed by a period of lethargy. Absence seizures are most common in children. They affect both sides of the brain.

<span class="mw-page-title-main">Oxcarbazepine</span> Anticonvulsant medication

Oxcarbazepine, sold under the brand name Trileptal among others, is a medication used to treat epilepsy. For epilepsy it is used for both focal seizures and generalized seizures. It has been used both alone and as add-on therapy in people with bipolar disorder who have had no success with other treatments. It is taken by mouth.

<span class="mw-page-title-main">Levetiracetam</span> Medication

Levetiracetam, sold under the brand name Keppra among others, is a novel antiepileptic drug (medication) used to treat epilepsy. It is used for partial-onset, myoclonic, or tonic–clonic seizures, and is taken either by mouth as an immediate or extended release formulation or by injection into a vein.

<span class="mw-page-title-main">Valpromide</span> Chemical compound

Valpromide is a carboxamide derivative of valproic acid used in the treatment of epilepsy and some affective disorders. It is rapidly metabolised (80%) to valproic acid but has anticonvulsant properties itself. It may produce more stable plasma levels than valproic acid or sodium valproate and may be more effective at preventing febrile seizures. However, it is over one hundred times more potent as an inhibitor of liver microsomal epoxide hydrolase. This makes it incompatible with carbamazepine and can affect the ability of the body to remove other toxins. Valpromide is no safer during pregnancy than valproic acid.

<span class="mw-page-title-main">Tiagabine</span> Anticonvulsant medication

Tiagabine is an anticonvulsant medication produced by Cephalon that is used in the treatment of epilepsy. The drug is also used off-label in the treatment of anxiety disorders and panic disorder.

<span class="mw-page-title-main">Clobazam</span> Benzodiazepine class medication

Clobazam, sold under the brand names Frisium, Onfi and others, is a benzodiazepine class medication that was patented in 1968. Clobazam was first synthesized in 1966 and first published in 1969. Clobazam was originally marketed as an anxioselective anxiolytic since 1970, and an anticonvulsant since 1984. The primary drug-development goal was to provide greater anxiolytic, anti-obsessive efficacy with fewer benzodiazepine-related side effects.

<span class="mw-page-title-main">Stiripentol</span> Anticonvulsant medication

Stiripentol, sold under the brand name Diacomit, is an anticonvulsant medication used for the treatment of Dravet syndrome - a serious genetic brain disorder.

<span class="mw-page-title-main">Sodium phenylbutyrate</span> Chemical compound

Sodium phenylbutyrate, sold under the brand name Buphenyl among others, is a salt of an aromatic fatty acid, 4-phenylbutyrate (4-PBA) or 4-phenylbutyric acid. The compound is used to treat urea cycle disorders, because its metabolites offer an alternative pathway to the urea cycle to allow excretion of excess nitrogen.

The emphasis of the treatment of bipolar disorder is on effective management of the long-term course of the illness, which can involve treatment of emergent symptoms. Treatment methods include pharmacological and psychological techniques.

Histone deacetylase inhibitors are chemical compounds that inhibit histone deacetylases. Since deacetylation of histones produces transcriptionally silenced heterochromatin, HDIs can render chromatin more transcriptionally active and induce epigenomic changes.

<span class="mw-page-title-main">Seletracetam</span> Chemical compound

Seletracetam is a pyrrolidone-derived drug of the racetam family that is structurally related to levetiracetam. It was under development by UCB Pharmaceuticals as a more potent and effective anticonvulsant drug to replace levetiracetam but its development has been halted.

<span class="mw-page-title-main">Lacosamide</span> Anticonvulsant and analgesic medication

Lacosamide, sold under the brand name Vimpat among others, is a medication used for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures. It is used by mouth or intravenously.

<span class="mw-page-title-main">Eslicarbazepine acetate</span> Anticonvulsant medication

Eslicarbazepine acetate (ESL), sold under the brand names Aptiom and Zebinix among others, is an anticonvulsant medication approved for use in Europe and the United States as monotherapy or as additional therapy for partial-onset seizures epilepsy.

Antimanic drugs are psychotropic drugs that are used to treat symptoms of mania. Though there are different causes of mania, the majority is caused by bipolar disorder, therefore antimanic drugs are mostly similar to drugs treating bipolar disorder. Since 1970s, antimanic drugs have been used specifically to control the abnormal elevation of mood or mood swings during manic episodes. One purpose of antimanic drugs is to alleviate or shorten the duration of an acute mania. Another objective is to prevent further cycles of mania and maintain the improvement achieved during the acute episode. The mechanism of antimanic drugs has not yet been fully known, it is proposed that they mostly affect chemical neurotransmitters in the brain. However, the usage of antimanic drugs should be consulted with a doctor or pharmacist due to their side effects and interactions with other drugs and food.

<span class="mw-page-title-main">Fetal valproate spectrum disorder</span> Medical condition

Fetal valproate spectrum disorder (FVSD), previously known as fetal valproate syndrome (FVS), is a rare disease caused by prenatal exposure to valproic acid (VPA), a medication commonly used to treat epilepsy, bipolar disorder, and migraines. This exposure can lead to a range of neurodevelopmental and physical symptoms, including cognitive impairments, developmental delays, autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), and congenital malformations.

References

  1. ↑ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 3 August 2023.
  2. ↑ "Product monograph brand safety updates". Health Canada . 7 July 2016. Retrieved 13 July 2024.
  3. 1 2 3 "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 "Depakote- divalproex sodium tablet, delayed release". Archived from the original on 5 March 2016. Retrieved 10 November 2015.
  5. 1 2 3 4 "Depakote ER- divalproex sodium tablet, extended release". DailyMed. 24 February 2023. Archived from the original on 28 January 2023. Retrieved 19 February 2024.
  6. 1 2 3 4 "Depakene, Stavzor (valproic acid) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 21 February 2014. Retrieved 13 February 2014.
  7. 1 2 3 4 5 6 7 8 9 10 11 "Valproic Acid". The American Society of Health-System Pharmacists. 24 November 2020. Archived from the original on 31 July 2017.
  8. ↑ "Valproate banned without the pregnancy prevention programme". GOV.UK. Archived from the original on 24 April 2018. Retrieved 26 April 2018.
  9. ↑ "Drug Safety Update - Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met". GOV.UK - Medicines and Healthcare products Regulatory Agency. 24 April 2018. Archived from the original on 7 January 2023. Retrieved 17 April 2022.
  10. ↑ "Men on sodium valproate told to use contraception". BBC News. BBC. Retrieved 5 September 2024.
  11. ↑ "FDA Information on Valporate" (PDF).
  12. ↑ Davis N (17 April 2022). "Sodium valproate: what are dangers of epilepsy drug for unborn babies?". The Observer. Archived from the original on 28 July 2022. Retrieved 17 April 2022.
  13. ↑ Owens MJ, Nemeroff CB (2003). "Pharmacology of valproate". Psychopharmacology Bulletin. 37 (Suppl 2): 17–24. PMID   14624230.
  14. 1 2 3 Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, et al. (April 2013). "Valproic acid pathway: pharmacokinetics and pharmacodynamics". Pharmacogenetics and Genomics. 23 (4): 236–241. doi:10.1097/FPC.0b013e32835ea0b2. PMC   3696515 . PMID   23407051.
  15. ↑ "Valproic acid". DrugBank. University of Alberta. 29 July 2017. Archived from the original on 31 July 2017. Retrieved 30 July 2017.
  16. ↑ Santos R, Linker SB, Stern S, Mendes AP, Shokhirev MN, Erikson G, et al. (June 2021). "Deficient LEF1 expression is associated with lithium resistance and hyperexcitability in neurons derived from bipolar disorder patients". Molecular Psychiatry. 26 (6): 2440–2456. doi:10.1038/s41380-020-00981-3. PMC   9129103 . PMID   33398088.
  17. ↑ Scott DF (1993). The history of epileptic therapy : an account of how medication was developed (1st ed.). Carnforth u.a.: Parthenon Publ. Group. p. 131. ISBN   978-1-85070-391-4. Archived from the original on 14 January 2023. Retrieved 17 September 2017.
  18. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl: 10665/371090 . WHO/MHP/HPS/EML/2023.02.
  19. ↑ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  20. ↑ "Valproate Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  21. 1 2 3 Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN   978-0-9805790-9-3.
  22. ↑ Löscher W (2002). "Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy". CNS Drugs. 16 (10): 669–694. doi:10.2165/00023210-200216100-00003. PMID   12269861. S2CID   67999301.
  23. ↑ Olsen KB, Taubøll E, Gjerstad L (2007). "Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults". Acta Neurologica Scandinavica. Supplementum. 187: 51–54. doi:10.1111/j.1600-0404.2007.00847.x. PMID   17419829. S2CID   11159645.
  24. ↑ Kwan SY (June 2010). "The role of intravenous valproate in convulsive status epilepticus in the future" (PDF). Editorial. Acta Neurologica Taiwanica. 19 (2): 78–81. PMID   20830628. Archived (PDF) from the original on 19 February 2024. Retrieved 19 February 2024.
  25. ↑ "Valproate Information". U.S. Food and Drug Administration (FDA). Archived from the original on 3 May 2015. Retrieved 24 April 2015.
  26. ↑ Jochim J, Rifkin-Zybutz RP, Geddes J, Cipriani A (October 2019). "Valproate for acute mania". The Cochrane Database of Systematic Reviews. 2019 (10): CD004052. doi:10.1002/14651858.CD004052.pub2. PMC   6797024 . PMID   31621892.
  27. 1 2 Wang Y, Xia J, Helfer B, Li C, Leucht S (November 2016). "Valproate for schizophrenia". The Cochrane Database of Systematic Reviews. 2016 (11): CD004028. doi:10.1002/14651858.CD004028.pub4. PMC   6734130 . PMID   27884042. Archived from the original on 29 July 2017. Retrieved 27 July 2017.
  28. ↑ Pirritano D, Plastino M, Bosco D, Gallelli L, Siniscalchi A, De Sarro G (2014). "Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review". BioMed Research International. 2014: 728038. doi: 10.1155/2014/728038 . PMC   4119624 . PMID   25114917.
  29. ↑ Connolly B, Fox SH (January 2014). "Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease". Neurotherapeutics. 11 (1): 78–91. doi:10.1007/s13311-013-0238-x. PMC   3899484 . PMID   24288035.
  30. ↑ Averbeck BB, O'Sullivan SS, Djamshidian A (2014). "Impulsive and compulsive behaviors in Parkinson's disease". Annual Review of Clinical Psychology. 10: 553–580. doi:10.1146/annurev-clinpsy-032813-153705. PMC   4197852 . PMID   24313567.
  31. ↑ "Valproic acid: medicine used for bipolar disorder, epilepsy and migraine". nhs.uk. 27 September 2018. Retrieved 20 November 2024.
  32. ↑ Singh D, Gupta S, Verma I, Morsy MA, Nair AB, Ahmed AF (October 2021). "Hidden pharmacological activities of valproic acid: A new insight". Biomedicine & Pharmacotherapy. 142: 112021. doi: 10.1016/j.biopha.2021.112021 . PMID   34463268.
  33. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 "Valpro sodium valproate" (PDF). TGA eBusiness Services. Alphapharm Pty Limited. 16 December 2013. Archived from the original on 27 August 2021. Retrieved 14 February 2014.
  34. ↑ "Update on MHRA review into safe use of valproate". gov.uk/ Compendium. 12 December 2022.
  35. ↑ "Depakote 250mg Tablets - Summary of Product Characteristics". electronic Medicines Compendium. Sanofi. 28 November 2013. Archived from the original on 1 February 2014. Retrieved 18 January 2014.
  36. ↑ Wu S, Legido A, De Luca F (January 2004). "Effects of valproic acid on longitudinal bone growth". Journal of Child Neurology. 19 (1): 26–30. doi:10.1177/088307380401900105011. PMID   15032379. S2CID   19827846.
  37. ↑ Robinson PB, Harvey W, Belal MS (February 1988). "Inhibition of cartilage growth by the anticonvulsant drugs diphenylhydantoin and sodium valproate". British Journal of Experimental Pathology. 69 (1): 17–22. PMC   2013195 . PMID   3126792.
  38. ↑ Guo CY, Ronen GM, Atkinson SA (September 2001). "Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy". Epilepsia. 42 (9): 1141–1147. doi:10.1046/j.1528-1157.2001.416800.x. PMID   11580761. S2CID   25499280.
  39. ↑ "Could Depakote cause Mydriasis". eHealthMe.com. 18 November 2014. Archived from the original on 5 December 2014. Retrieved 24 April 2015.
  40. ↑ Bilo L, Meo R (October 2008). "Polycystic ovary syndrome in women using valproate: a review". Gynecological Endocrinology. 24 (10): 562–570. doi:10.1080/09513590802288259. PMID   19012099. S2CID   36426338.
  41. ↑ Chukwu J, Delanty N, Webb D, Cavalleri GL (January 2014). "Weight change, genetics and antiepileptic drugs". Expert Review of Clinical Pharmacology. 7 (1): 43–51. doi:10.1586/17512433.2014.857599. PMID   24308788. S2CID   33444886.
  42. ↑ "Fetal valproate spectrum disorder". Genetic and Rare Diseases Information Center . 2024. Archived from the original on 30 May 2024. Retrieved 31 May 2024.
  43. ↑ "Fetal valproate spectrum disorder". Orphanet . 2020. Archived from the original on 31 May 2024. Retrieved 31 May 2024.
  44. ↑ Clayton-Smith J, Bromley R, Dean J, Journel H, Odent S, Wood A, et al. (December 2019). "Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability". Orphanet Journal of Rare Diseases . 14 (1): 180. doi: 10.1186/s13023-019-1064-y . PMC   6642533 . PMID   31324220.
  45. 1 2 3 4 Suzanne B (11 December 2013). "Valproic Acid Level". Medscape. Archived from the original on 4 May 2015. Retrieved 5 June 2015.
  46. 1 2 3 4 "Free Valproic Acid Assay (Reference – 2013.03.006) Notice of Assessment" (PDF). Canadian Agency for Drugs and Technologies in Health (CADTH) with INESSS's permission. April 2014. Archived from the original (PDF) on 3 March 2016. Retrieved 5 June 2015.
  47. ↑ Sztajnkrycer MD (2002). "Valproic acid toxicity: overview and management". Journal of Toxicology. Clinical Toxicology. 40 (6): 789–801. doi:10.1081/CLT-120014645. PMID   12475192. S2CID   23031095.
  48. ↑ Patsalos PN, Berry DJ (February 2013). "Therapeutic drug monitoring of antiepileptic drugs by use of saliva". Therapeutic Drug Monitoring. 35 (1): 4–29. doi:10.1097/FTD.0b013e31827c11e7. PMID   23288091. S2CID   15338188.
  49. ↑ Thanacoody RH (August 2009). "Extracorporeal elimination in acute valproic acid poisoning". Clinical Toxicology. 47 (7): 609–616. doi:10.1080/15563650903167772. PMID   19656009. S2CID   13592043.
  50. ↑ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1622–1626.
  51. 1 2 Lheureux PE, Penaloza A, Zahir S, Gris M (October 2005). "Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?". Critical Care. 9 (5): 431–440. doi: 10.1186/cc3742 . PMC   1297603 . PMID   16277730.
  52. ↑ Mock CM, Schwetschenau KH (January 2012). "Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy". American Journal of Health-System Pharmacy. 69 (1): 35–39. doi:10.2146/ajhp110049. PMID   22180549.
  53. ↑ Matsuoka M, Igisu H (July 1993). "Comparison of the effects of L-carnitine, D-carnitine and acetyl-L-carnitine on the neurotoxicity of ammonia". Biochemical Pharmacology. 46 (1): 159–164. doi:10.1016/0006-2952(93)90360-9. PMID   8347126.
  54. ↑ Herzog AG, Farina EL, Blum AS (June 2005). "Serum valproate levels with oral contraceptive use". Epilepsia. 46 (6): 970–971. doi: 10.1111/j.1528-1167.2005.00605.x . PMID   15946343. S2CID   7696039.
  55. ↑ Kay HY, Greene DL, Kang S, Kosenko A, Hoshi N (October 2015). "M-current preservation contributes to anticonvulsant effects of valproic acid". The Journal of Clinical Investigation. 125 (10): 3904–3914. doi:10.1172/JCI79727. PMC   4607138 . PMID   26348896.
  56. ↑ Chang P, Walker MC, Williams RS (February 2014). "Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid". Neurobiology of Disease. 62: 296–306. doi:10.1016/j.nbd.2013.10.017. PMC   3898270 . PMID   24148856.
  57. ↑ Sakai K, Hara K, Tanemura K (3 September 2023). "Testicular histone hyperacetylation in mice by valproic acid administration affects the next generation by changes in sperm DNA methylation". PLOS ONE. 18 (3): e0282898. Bibcode:2023PLoSO..1882898S. doi: 10.1371/journal.pone.0282898 . PMC   9997898 . PMID   36893188.
  58. ↑ Kostrouchová M, Kostrouch Z, Kostrouchová M (2007). "Valproic acid, a molecular lead to multiple regulatory pathways" (PDF). Folia Biologica. 53 (2): 37–49. PMID   17448293. Archived from the original (PDF) on 21 February 2014. Retrieved 13 February 2014.
  59. 1 2 Chiu CT, Wang Z, Hunsberger JG, Chuang DM (January 2013). "Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder". Pharmacological Reviews. 65 (1): 105–142. doi:10.1124/pr.111.005512. PMC   3565922 . PMID   23300133.
  60. 1 2 Death AK, McGrath KC, Handelsman DJ (December 2005). "Valproate is an anti-androgen and anti-progestin". Steroids. 70 (14): 946–953. doi:10.1016/j.steroids.2005.07.003. hdl: 10453/16875 . PMID   16165177. S2CID   25958985.
  61. 1 2 Wyllie E, Cascino GD, Gidal BE, Goodkin HP (17 February 2012). Wyllie's Treatment of Epilepsy: Principles and Practice. Lippincott Williams & Wilkins. pp. 288–. ISBN   978-1-4511-5348-4. Archived from the original on 6 June 2014.
  62. ↑ Uchida H, Maruyama T, Arase T, Ono M, Nagashima T, Masuda H, et al. (June 2005). "Histone acetylation in reproductive organs: Significance of histone deacetylase inhibitors in gene transcription". Reproductive Medicine and Biology. 4 (2): 115–122. doi:10.1111/j.1447-0578.2005.00101.x. PMC   5891791 . PMID   29662388.
  63. 1 2 Isojärvi JI, Taubøll E, Herzog AG (2005). "Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy". CNS Drugs. 19 (3): 207–223. doi:10.2165/00023210-200519030-00003. PMID   15740176. S2CID   9893959.
  64. 1 2 3 4 5 6 Haberfeld H, ed. (2021). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Depakine chrono retard 300 mg Filmtabletten.
  65. ↑ Kumar S, Wong H, Yeung SA, Riggs KW, Abbott FS, Rurak DW (July 2000). "Disposition of valproic acid in maternal, fetal, and newborn sheep. II: metabolism and renal elimination". Drug Metabolism and Disposition. 28 (7): 857–864. PMID   10859160.
  66. ↑ Schneemann H, Young L, Koda-Kimble MA, eds. (2001). Angewandte Arzneimitteltherapie (in German). Springer. pp. 28–29. ISBN   3-540-41356-1.
  67. 1 2 Valproate FDA Professional Drug Information . Accessed 6 August 2021.
  68. 1 2 3 4 5 6 7 8 "Valproic Acid". DrugBank. University of Alberta. 31 August 2017. Archived from the original on 31 July 2017. Retrieved 1 September 2017.
  69. ↑ Burton BS (1882). "On the propyl derivatives and decomposition products of ethylacetoacetate". Am. Chem. J. 3: 385–395.
  70. ↑ Meunier H, Carraz G, Neunier Y, Eymard P, Aimard M (1963). "[Pharmacodynamic properties of N-dipropylacetic acid]" [Pharmacodynamic properties of N-dipropylacetic acid]. Therapie (in French). 18: 435–438. PMID   13935231.
  71. ↑ Perucca E (2002). "Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience". CNS Drugs. 16 (10): 695–714. doi:10.2165/00023210-200216100-00004. PMID   12269862. S2CID   803106.
  72. ↑ Henry TR (2003). "The history of valproate in clinical neuroscience". Psychopharmacology Bulletin. 37 (Suppl 2): 5–16. PMID   14624229.
  73. ↑ Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN   978-0-85711-084-8.
  74. ↑ Rimmer EM, Richens A (May–June 1985). "An update on sodium valproate". Pharmacotherapy. 5 (3): 171–184. doi:10.1002/j.1875-9114.1985.tb03413.x. PMID   3927267. S2CID   7700266.
  75. ↑ Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. (March 2010). "Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy". The New England Journal of Medicine. 362 (9): 790–799. doi:10.1056/NEJMoa0902014. PMC   2924476 . PMID   20200383.
  76. ↑ Jiang M (6 April 2015). "Co-Administration of Valproic Acid and Lamotrigine in the Treatment of Refractory Epilepsy (P1.238)" . Neurology. 84 (14 Supplement): P1.238. doi:10.1212/WNL.84.14_supplement.P1.238. S2CID   74543829. Archived from the original on 27 August 2021. Retrieved 4 May 2015– via www.neurology.org.
  77. ↑ Berendsen S, Kroonen J, Seute T, Snijders T, Broekman ML, Spliet WG, et al. (1 September 2014). "O9.06 * Prognostic Relevance and Oncogenic Correlates of Epilepsy in Glioblastoma Patients". Neuro-Oncology. 16 (suppl_2): ii21. doi:10.1093/neuonc/nou174.77. PMC   4185847 .
  78. ↑ Vasudev K, Mead A, Macritchie K, Young AH (2012). "Valproate in acute mania: is our practice evidence based?". International Journal of Health Care Quality Assurance. 25 (1): 41–52. doi:10.1108/09526861211192395. PMID   22455007.
  79. ↑ Bond DJ, Lam RW, Yatham LN (August 2010). "Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis". Journal of Affective Disorders. 124 (3): 228–234. doi:10.1016/j.jad.2009.11.008. PMID   20044142.
  80. ↑ Haddad PM, Das A, Ashfaq M, Wieck A (May 2009). "A review of valproate in psychiatric practice". Expert Opinion on Drug Metabolism & Toxicology. 5 (5): 539–551. doi:10.1517/17425250902911455. PMID   19409030. S2CID   74028228.
  81. ↑ Frazee LA, Foraker KC (March 2008). "Use of intravenous valproic acid for acute migraine". The Annals of Pharmacotherapy. 42 (3): 403–407. doi:10.1345/aph.1K531. PMID   18303140. S2CID   207263036.
  82. ↑ Wang Y, Xia J, Helfer B, Li C, Leucht S (November 2016). "Valproate for schizophrenia". The Cochrane Database of Systematic Reviews. 2016 (11): CD004028. doi:10.1002/14651858.CD004028.pub4. PMC   6734130 . PMID   27884042.
  83. 1 2 Baillon SF, Narayana U, Luxenberg JS, Clifton AV (October 2018). "Valproate preparations for agitation in dementia". The Cochrane Database of Systematic Reviews. 2018 (10): CD003945. doi:10.1002/14651858.CD003945.pub4. PMC   6516950 . PMID   30293233.
  84. ↑ Gill D, Derry S, Wiffen PJ, Moore RA (October 2011). "Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 2011 (10): CD009183. doi:10.1002/14651858.CD009183.pub2. PMC   6540387 . PMID   21975791.
  85. ↑ Aliyev ZN, Aliyev NA (July–August 2008). "Valproate treatment of acute alcohol hallucinosis: a double-blind, placebo-controlled study". Alcohol and Alcoholism. 43 (4): 456–459. doi: 10.1093/alcalc/agn043 . PMID   18495806.
  86. ↑ Jacobson PL, Messenheimer JA, Farmer TW (November 1981). "Treatment of intractable hiccups with valproic acid". Neurology. 31 (11): 1458–1460. doi:10.1212/WNL.31.11.1458. PMID   6796902. S2CID   1578958.
  87. ↑ Sotaniemi K (July 1982). "Valproic acid in the treatment of nonepileptic myoclonus". Archives of Neurology. 39 (7): 448–449. doi:10.1001/archneur.1982.00510190066025. PMID   6808975.
  88. ↑ Wheeler SD (July–August 1998). "Significance of migrainous features in cluster headache: divalproex responsiveness". Headache. 38 (7): 547–551. doi: 10.1046/j.1526-4610.1998.3807547.x . PMID   15613172. S2CID   27948702.
  89. ↑ Siemes H, Spohr HL, Michael T, Nau H (September–October 1988). "Therapy of infantile spasms with valproate: results of a prospective study". Epilepsia. 29 (5): 553–560. doi:10.1111/j.1528-1157.1988.tb03760.x. PMID   2842127. S2CID   23789333.
  90. ↑ Smith SM (September 2005). "Valproic acid and HIV-1 latency: beyond the sound bite". Retrovirology. 2 (1): 56. doi: 10.1186/1742-4690-2-56 . PMC   1242254 . PMID   16168066.
  91. ↑ Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, et al. (May 2012). "Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study". HIV Medicine. 13 (5): 291–296. doi: 10.1111/j.1468-1293.2011.00975.x . PMID   22276680. S2CID   27571864.
  92. ↑ Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, et al. (February 2010). "Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection". PLOS ONE. 5 (2): e9390. Bibcode:2010PLoSO...5.9390A. doi: 10.1371/journal.pone.0009390 . PMC   2826423 . PMID   20186346.
  93. 1 2 Hardy JR, Rees EA, Gwilliam B, Ling J, Broadley K, A'Hern R (March 2001). "A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain". Journal of Pain and Symptom Management. 21 (3): 204–209. doi: 10.1016/S0885-3924(00)00266-9 . PMID   11239739.[ permanent dead link ]
  94. ↑ Candelaria M, Herrera A, Labardini J, González-Fierro A, Trejo-Becerril C, Taja-Chayeb L, et al. (April 2011). "Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial". Annals of Hematology. 90 (4): 379–387. doi:10.1007/s00277-010-1090-2. PMID   20922525. S2CID   13437134.
  95. ↑ Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, et al. (December 2005). "Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia". Cancer. 104 (12): 2717–2725. doi:10.1002/cncr.21589. PMID   16294345. S2CID   1802132.
  96. ↑ Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, et al. (January 2006). "The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia". Cancer. 106 (1): 112–119. doi: 10.1002/cncr.21552 . PMID   16323176. S2CID   43747497.
  97. ↑ Fredly H, Gjertsen BT, Bruserud O (July 2013). "Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents". Clinical Epigenetics. 5 (1): 12. doi: 10.1186/1868-7083-5-12 . PMC   3733883 . PMID   23898968.
  98. ↑ Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, González-Fierro A, de la Cruz-Hernandez E, et al. (December 2011). "A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results". Medical Oncology. 28 (Suppl 1): S540–S546. doi:10.1007/s12032-010-9700-3. PMID   20931299. S2CID   207372333.
  99. ↑ Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, et al. (January 2009). "A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma". British Journal of Cancer. 100 (1): 28–36. doi:10.1038/sj.bjc.6604817. PMC   2634690 . PMID   19127265.
  100. ↑ Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, et al. (April 2009). "Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC". Clinical Cancer Research. 15 (7): 2488–2496. doi:10.1158/1078-0432.CCR-08-1930. PMID   19318486. S2CID   3230087.
  101. ↑ Hicks CW, Pandya MM, Itin I, Fernandez HH (June 2011). "Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease". Parkinsonism & Related Disorders. 17 (5): 379–381. doi:10.1016/j.parkreldis.2011.03.003. PMID   21459656.
  102. ↑ Sriram A, Ward HE, Hassan A, Iyer S, Foote KD, Rodriguez RL, et al. (February 2013). "Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease". Journal of Neurology. 260 (2): 521–527. doi:10.1007/s00415-012-6669-1. PMID   23007193. S2CID   21544457.
  103. ↑ Aizenman NC (7 May 2012). "Abbott Laboratories to pay $1.6 billion over illegal marketing of Depakote". Washington Post. Archived from the original on 28 June 2018. Retrieved 27 June 2018.
  104. ↑ Schmidt M, Thomas K (8 May 2012). "Abbott settles marketing lawsuit". New York Times. Archived from the original on 28 June 2018. Retrieved 27 June 2018.
  105. ↑ Gervain J, Vines BW, Chen LM, Seo RJ, Hensch TK, Werker JF, et al. (2013). "Valproate reopens critical-period learning of absolute pitch". Frontiers in Systems Neuroscience. 7: 102. doi: 10.3389/fnsys.2013.00102 . PMC   3848041 . PMID   24348349.
  106. ↑ Thomson H. "Learning drugs reawaken grown-up brain's inner child". New Scientist. New Scientist Ltd. Archived from the original on 8 May 2021. Retrieved 8 May 2021.
  107. ↑ "Valproate sodium injection". DailyMed. 1 January 2021. Archived from the original on 8 October 2022. Retrieved 7 October 2022.
  108. ↑ "Valproate sodium injection, solution". DailyMed. 29 April 2021. Archived from the original on 9 October 2022. Retrieved 7 October 2022.
  109. ↑ Taylor D, Paton C, Kapur S (2009). The Maudsley Prescribing Guidelines (Tenth ed.). CRC Press. p. 124. ISBN   978-0-203-09283-5. Archived from the original on 14 January 2023. Retrieved 17 September 2017.
  110. ↑ Brayfield A (ed.). Martindale: The Complete Drug Reference. London: Pharmaceutical Press. Archived from the original on 27 August 2021. Retrieved 3 March 2018.
  111. ↑ "Depakene- valproic acid capsule, liquid filled". DailyMed. 19 September 2019. Archived from the original on 11 July 2020. Retrieved 14 April 2020.
  112. ↑ "Depakin - Banca Dati Farmaci dell'AIFA" [Depakin - The AIFA Medicines Database]. farmaci.agenziafarmaco.gov.it (in Italian). Italian Medicines Agency. 6 June 2023. Archived from the original on 6 June 2023. Retrieved 6 June 2023.
  113. 1 2 3 4 "Australian product information epilim (sodium valproate) crushable tablets, enteric-coated tablets, syrup, liquid" (PDF). TGA eBS. 15 April 2020. Archived from the original on 15 March 2020. Retrieved 15 April 2020.
  114. ↑ "Sodium valproate -- Pharmaceutical Schedule". Pharmaceutical Management Agency. Archived from the original on 4 March 2016. Retrieved 22 June 2014.
  115. ↑ "South African Electronic Package Inserts: Convulex". Archived from the original on 12 August 2010. Retrieved 2 January 2006.
  116. ↑ "Malaysian Package Inserts: Epilim". Archived from the original on 5 June 2023. Retrieved 5 June 2023.
  117. ↑ Treadwell JR, Wu M, Tsou AY (October 2022). Management of Infantile Epilepsies . effectivehealthcare.ahrq.gov (Report). Rockville (MD): Agency for Healthcare Research and Quality (US). doi:10.23970/ahrqepccer252. PMID   36383706. Report No.: 22(23)-EHC004 Report No.: 2021-SR-01. Archived from the original on 5 July 2023. Retrieved 12 July 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.